-+ 0.00%
-+ 0.00%
-+ 0.00%

GenFleet schedules Oct. 15 investor call to release preliminary GFH375-cetuximab trial data in KRAS G12D tumors

PUBT·09/23/2026 00:03:06
GenFleet schedules Oct. 15 investor call to release preliminary GFH375-cetuximab trial data in KRAS G12D tumors
  • GenFleet set October 15, 2026 for releasing preliminary study data on GFH375 combined with cetuximab in KRAS G12D-mutant tumors.
  • Results have not been presented yet; disclosure is scheduled via an online investor call.
  • Verastem will outline ex-China progress for the partnered GFH375 program on October 14, 2026, ahead of GenFleet’s update.
  • GFH276 monotherapy data in RAS-mutant solid tumors was selected for a late-breaking oral presentation at ESMO 2026 on October 25.
  • GenFleet plans an online investor call on October 25, 2026 to interpret the GFH276 presentation and its early clinical readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260923-12342099), on September 23, 2026, and is solely responsible for the information contained therein.